Argenx
ARGX
#449
Rank
NZ$94.02 B
Marketcap
NZ$1,505
Share price
-0.84%
Change (1 day)
56.20%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$27.14. In 2024 the company made an earnings per share (EPS) of NZ$23.89 an increase over its 2023 EPS that were of NZ-$8.86.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23
2024NZ$23.89-369.77%
2023NZ-$8.86-60.46%
2022NZ-$22.4063.33%
2021NZ-$13.71-40.37%
2020NZ-$23.00183.47%
2019NZ-$8.11123.09%
2018NZ-$3.6454.93%
2017NZ-$2.3514.07%
2016NZ-$2.0613.05%
2015NZ-$1.82-36.34%
2014NZ-$2.86209.04%
2013NZ-$0.93-33.99%
2012NZ-$1.40185.59%
2011NZ-$0.49